Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus. Local targets link to admitted publications; unresolved targets remain external evidence.
Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: a population-based study
10.1111/cas.15262 · 2022 · External reference
How we treat esophageal squamous cell carcinoma
10.1016/j.esmoop.2023.100789 · 2023 · External reference
Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma
10.1056/nejmoa2111380 · 2022 · External reference
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
10.1016/s0140-6736(21)01234-4 · 2021 · External reference
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
10.1016/s1470-2045(23)00108-0 · 2023 · External reference
PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
10.1186/s12885-021-08958-3 · 2021 · External reference
Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?
10.1177/17588359231189420 · 2023 · External reference
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(19)30626-6 · 2019 · External reference
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
10.1084/jem.20100643 · 2010 · External reference
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
10.1186/s13045-023-01499-1 · 2023 · External reference
Abstract 2270: RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells
10.1158/1538-7445.am2020-2270 · 2020 · External reference
Tobemstomig, a novel bi-specific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control
10.1158/2767-9764.crc-26-0207 · 2026 · External reference
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma
10.1158/1078-0432.ccr-25-4478 · 2026 · External reference
CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer
10.3390/cancers11091398 · 2019 · External reference
EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells
10.1038/s42003-024-07341-9 · 2024 · External reference
A composite decision rule of CD8+ T-cell density in tumor biopsies predicts efficacy in early-stage, immunotherapy trials
10.1158/1078-0432.ccr-23-1572 · 2024 · External reference
Investigation into the expression levels of MAGEA6 in esophageal squamous cell carcinoma and esophageal adenocarcinoma tissues
10.3892/etm.2019.7735 · 2019 · External reference
MAGEA6 positively regulates MSMO1 and promotes the migration and invasion of oesophageal cancer cells
10.3892/etm.2022.11127 · 2022 · External reference
A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy
10.1080/2162402x.2020.1781333 · 2020 · External reference
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
10.1200/jco.20.01888 · 2020 · External reference
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
10.1038/s41586-022-05192-0 · 2022 · External reference
Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses
10.4161/21624011.2014.954501 · 2014 · External reference
Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay
10.1007/s00262-012-1298-1 · 2012 · External reference
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes
10.1126/sciimmunol.aah4569 · 2017 · External reference
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
10.1172/jci164809 · 2023 · External reference
